ProteoDesign, founded in 2012 and CataloniaBio & HealthTech member, rebrands as Splice Bio to develop novel gene therapies throught its proprietary platform based on technology developed in the Muir Lab at Princeton University.
The Barcelona-based biotech company also announces a new investment led by Ysios Capital and joined by Asabys Partners. This financing round was organised thanks to the support of existing shareholder Caixa Capital Risc.
Splice Bio pioneering platform has the potential to target genetic diseases that cannot be addressed with current gene therapies. Specifically, it has the potential to address two existing limitations of adeno-associated viruses (AAVs) as vectors for gene therapy, both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
Photo: from left to right, Miquel Vila-Perelló, co-founder and CEO of Splice Bio; Silvia Frutos, co-founder and CSO, and Gerard Caelles, Chief Business Officer - © Splice Bio
You also may be interested in:
Comments